~ Dec 07 Hope For Autism Sufferers - References
References
1. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004 May;113(5):e472-86.
2. Baker SM. Part II: Notes on treatment options. In: Pangborn JB, Baker SM, editors. Biomedical Assessment Options for Children with Autism and Related Problems. San Diego, CA: Autism Research Institute; 2002.
3. Kidd PM. Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base. Altern Med Rev. 2002 Aug;7(4):292-316.
4. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. Neuron. 2000 Nov;28(2):355-63.
5. Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99.
6. Serajee FJ, Nabi R, Zhong H, Huq M. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol. 2004 Jun;19(6):413-7.
7. Sogut S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003 May;331(1-2):111-7.
8. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002 Jun;4(3):251-8.
9. Zilbovicius M, Garreau B, Samson Y, et al. Delayed maturation of the frontal cortex in childhood autism. Am J Psychiatry. 1995 Feb;152(2):248-52.
10. Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol. 1997 Jul;17(1):88-90.
11. Chez MG, Chin K, Hung PC. Immunizations, immunology, and autism. Semin Pediatr Neurol. 2004 Sep;11(3):214-7.
12. DeStefano F, Thompson WW. MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines. 2004 Feb;3(1):19-22.
13. Fitzpatrick M. MMR: risk, choice, chance. Br Med Bull. 2004;69:143-53.
14. Bradstreet J, Kartzinel J. Biological interventions in the treatment of autism and PDD. San Diego, CA: Autism Research Institute; 2001.
15. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S162-71.
16. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006 Apr;36(3):413-20.
17. Shattock P, Whiteley P. The Sunderland Protocol: A Logical Sequencing of Biomedical Interventions for the Treatment of Autism and Related Disorders. Sunderland, UK: Autism Research Unit, University of Sunderland;2002.
18. Vojdani A, O'Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci. 2004 Jun;7(3):151-61.
19. Shattock P, Hooper M, Waring R. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2004 May;46(5):357-8.
20. Vojdani A, Pangborn JB, Vojdani E, Cooper EL. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol. 2003 Sep;16(3):189-99.
21. Brudnak MA, Rimland B, Kerry RE, et al. Enzyme-based therapy for autism spectrum disorders -- is it worth another look? Med Hypotheses. 2002 May;58(5):422-8.
22. Kirkman Laboratories. The Kirkman Guide to Intestinal Health in Autism Spectrum Disorders. Lake Oswego, OR: Kirkman Laboratories;2002.
23. Brudnak MA. Probiotics as an adjuvant to detoxification protocols. Med Hypotheses. 2002 May;58(5):382-5.
24. Garvey J. Diet in autism and associated disorders. J Fam Health Care. 2002;12(2):34-8.
25. Song Y, Liu C, Finegold SM. Real-time PCR quantification of clostridia in feces of autistic children. Appl Environ Microbiol. 2004 Nov;70(11):6459-65.
26. Wakefield AJ, Puleston JM, Montgomery SM et al. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther. 2002 Apr;16(4):663-74.
27. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000 Jul;15(7):429-35.
28. Page T. Metabolic approaches to the treatment of autism spectrum disorders. J Autism Dev Disord. 2000 Oct;30(5):463-9.
29. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004 Dec;10(6):1033-9.
30. Rimland B. The use of vitamin B6, magnesium, and DMG in the treatment of autistic children and adults. In: Shaw W, editor. Biological Treatments for Autism and PDD. Lenexa, KS: The Great Plains Laboratory, Inc; 2005.
31. Levy SE, Hyman SL. Use of complementary and alternative treatments for children with autistic spectrum disorders is increasing. Pediatr Ann. 2003 Oct;32(10):685-91.
32. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978 Apr;135(4):472-5.
33. Lelord G, Muh JP, Barthelemy C et al. Effects of pyridoxine and magnesium on autistic symptoms--initial observations. J Autism Dev Disord. 1981 Jun;11(2):219-30.
34. Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4(1-2):27-44.
35. Martineau J, Barthelemy C, Cheliakine C, Lelord G. Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988 Sep;18(3):435-47.
36. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006 Mar;19(1):53-62.
37. Clark JH, Rhoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. JPEN J Parenter Enteral Nutr. 1993 May;17(3):284-6.
38. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000 Jun;54(6):979-83.
39. McGinnis WR. Oxidative stress in autism. Altern Ther Health Med. 2004 Nov;10(6):22-36.
40. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):765-74.
41. McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology. 1996 Jul 17;111(1-3):43-65.
42. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
43. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002 Aug;23(4):303-8.
44. No authors. Glutathione, reduced (GSH). Monograph. Altern Med Rev. 2001 Dec;6(6):601-7.
45. Moretti P, Sahoo T, Hyland K, et al. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology. 2005 Mar 22;64(6):1088-90.
46. Gillberg C, Wahlstrom J, Johansson R, Tornblom M, Bertsson-Wikland K. Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol. 1986 Oct;28(5):624-7.
47. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005 Oct;25(5):485-9.
48. Ortega TM, Andrés P, López-Sobaler A, et al. The role of folates in the diverse biochemical processes that control mental function. Nutr Hosp. 1994 Jul-Aug;9(4):251-6.
49. Available at: http://www.medscape.com/viewarticle/431514_side. Accessed September 27, 2007.
50. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007 Mar;36(3):152-8.
51. Alhamdani MS, Al-Kassir AH, Abbas FK, Jaleel NA, Al-Taee MF. Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin Pract. 2007;107(1):c26-34.
52. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov;17(11):833-7.
53. Bell JG, Sargent JR, Tocher DR, Dick JR. Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids. 2000 Jul;63(1-2):21-5.
54. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001 Jul;65(1):1-7.
55. Ward PE. Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders. Prostaglandins Leukot Essent Fatty Acids. 2000 Jul;63(1-2):65-8.
56. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004 Oct;71(4):201-4.
57. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001 Nov 1;120(1-2):170-9.
58. Grimm H, Mayer K, Mayser P, Eigenbrodt E. Regulatory potential of n-3 fatty acids in immunological and inflammatory processes. Br J Nutr. 2002 Jan;87 Suppl 1S59-S67.
59. De CR, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000 Jan;71(1 Suppl):213S-23S.
60. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007 Feb 15;61(4):551-3.
61. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11(2):131-42.
62. Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006 Aug;118(2):e534-6.
63. Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A. 2007 Jun;70(12):1046-51.
64. Soden SE, Lowry JA, Garrison CB, Wasserman GS. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila). 2007 Jun;45(5):476-81.
65. Ng DK, Chan CH, Soo MT, Lee RS. Low-level chronic mercury exposure in children and adolescents: meta-analysis. Pediatr Int. 2007 Feb;49(1):80-7.
66. Kirkman Laboratories. Detoxification of heavy metals in the treatment of autism. A Guide to Scientific Nutrition for Autism and Related Conditions. Lake Oswego, OR: Kirkman Laboratories; 2002.
67. Shannon M, Woolf A, Goldman R. Children's environmental health: one year in a pediatric environmental health specialty unit. Ambul Pediatr. 2003 Jan;3(1):53-6.
68. Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007 May 15;70(10):837-51.
69. Chisolm JJ, Jr. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations.J Toxicol Clin Toxicol. 2000;38(4):365-75.
70. Graziano JH, Lolacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr. 1992 Jan;120(1):133-9.
71. Karunasagar D, Krishna MV, Rao SV, Arunachalam J. Removal and preconcentration of inorganic and methyl mercury from aqueous media using a sorbent prepared from the plant Coriandrum sativum. J Hazard Mater. 2005 Feb 14;118(1-3):133-9.
72. Aga M, Iwaki K, Ueda Y, et al. Preventive effect of Coriandrum sativum (Chinese parsley) on localized lead deposition in ICR mice. J Ethnopharmacol. 2001 Oct;77(2-3):203-8.
73. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit. 2004 Mar;10(3):I33-9.
74. Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry. 2004 Sep;9(9):833-45.
75. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004 Sep;114(3):793-804.
76. Davidson PW, Myers GJ, Weiss B. Mercury exposure and child development outcomes. Pediatrics. 2004 Apr;113(4 Suppl):1023-9.
77. Halsey NA, Hyman SL. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics. 2001 May;107(5):E84.
1. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004 May;113(5):e472-86.
2. Baker SM. Part II: Notes on treatment options. In: Pangborn JB, Baker SM, editors. Biomedical Assessment Options for Children with Autism and Related Problems. San Diego, CA: Autism Research Institute; 2002.
3. Kidd PM. Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base. Altern Med Rev. 2002 Aug;7(4):292-316.
4. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. Neuron. 2000 Nov;28(2):355-63.
5. Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99.
6. Serajee FJ, Nabi R, Zhong H, Huq M. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol. 2004 Jun;19(6):413-7.
7. Sogut S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003 May;331(1-2):111-7.
8. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002 Jun;4(3):251-8.
9. Zilbovicius M, Garreau B, Samson Y, et al. Delayed maturation of the frontal cortex in childhood autism. Am J Psychiatry. 1995 Feb;152(2):248-52.
10. Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol. 1997 Jul;17(1):88-90.
11. Chez MG, Chin K, Hung PC. Immunizations, immunology, and autism. Semin Pediatr Neurol. 2004 Sep;11(3):214-7.
12. DeStefano F, Thompson WW. MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines. 2004 Feb;3(1):19-22.
13. Fitzpatrick M. MMR: risk, choice, chance. Br Med Bull. 2004;69:143-53.
14. Bradstreet J, Kartzinel J. Biological interventions in the treatment of autism and PDD. San Diego, CA: Autism Research Institute; 2001.
15. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S162-71.
16. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006 Apr;36(3):413-20.
17. Shattock P, Whiteley P. The Sunderland Protocol: A Logical Sequencing of Biomedical Interventions for the Treatment of Autism and Related Disorders. Sunderland, UK: Autism Research Unit, University of Sunderland;2002.
18. Vojdani A, O'Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci. 2004 Jun;7(3):151-61.
19. Shattock P, Hooper M, Waring R. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2004 May;46(5):357-8.
20. Vojdani A, Pangborn JB, Vojdani E, Cooper EL. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol. 2003 Sep;16(3):189-99.
21. Brudnak MA, Rimland B, Kerry RE, et al. Enzyme-based therapy for autism spectrum disorders -- is it worth another look? Med Hypotheses. 2002 May;58(5):422-8.
22. Kirkman Laboratories. The Kirkman Guide to Intestinal Health in Autism Spectrum Disorders. Lake Oswego, OR: Kirkman Laboratories;2002.
23. Brudnak MA. Probiotics as an adjuvant to detoxification protocols. Med Hypotheses. 2002 May;58(5):382-5.
24. Garvey J. Diet in autism and associated disorders. J Fam Health Care. 2002;12(2):34-8.
25. Song Y, Liu C, Finegold SM. Real-time PCR quantification of clostridia in feces of autistic children. Appl Environ Microbiol. 2004 Nov;70(11):6459-65.
26. Wakefield AJ, Puleston JM, Montgomery SM et al. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther. 2002 Apr;16(4):663-74.
27. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000 Jul;15(7):429-35.
28. Page T. Metabolic approaches to the treatment of autism spectrum disorders. J Autism Dev Disord. 2000 Oct;30(5):463-9.
29. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004 Dec;10(6):1033-9.
30. Rimland B. The use of vitamin B6, magnesium, and DMG in the treatment of autistic children and adults. In: Shaw W, editor. Biological Treatments for Autism and PDD. Lenexa, KS: The Great Plains Laboratory, Inc; 2005.
31. Levy SE, Hyman SL. Use of complementary and alternative treatments for children with autistic spectrum disorders is increasing. Pediatr Ann. 2003 Oct;32(10):685-91.
32. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978 Apr;135(4):472-5.
33. Lelord G, Muh JP, Barthelemy C et al. Effects of pyridoxine and magnesium on autistic symptoms--initial observations. J Autism Dev Disord. 1981 Jun;11(2):219-30.
34. Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4(1-2):27-44.
35. Martineau J, Barthelemy C, Cheliakine C, Lelord G. Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988 Sep;18(3):435-47.
36. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006 Mar;19(1):53-62.
37. Clark JH, Rhoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. JPEN J Parenter Enteral Nutr. 1993 May;17(3):284-6.
38. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000 Jun;54(6):979-83.
39. McGinnis WR. Oxidative stress in autism. Altern Ther Health Med. 2004 Nov;10(6):22-36.
40. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):765-74.
41. McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology. 1996 Jul 17;111(1-3):43-65.
42. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
43. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002 Aug;23(4):303-8.
44. No authors. Glutathione, reduced (GSH). Monograph. Altern Med Rev. 2001 Dec;6(6):601-7.
45. Moretti P, Sahoo T, Hyland K, et al. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology. 2005 Mar 22;64(6):1088-90.
46. Gillberg C, Wahlstrom J, Johansson R, Tornblom M, Bertsson-Wikland K. Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol. 1986 Oct;28(5):624-7.
47. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005 Oct;25(5):485-9.
48. Ortega TM, Andrés P, López-Sobaler A, et al. The role of folates in the diverse biochemical processes that control mental function. Nutr Hosp. 1994 Jul-Aug;9(4):251-6.
49. Available at: http://www.medscape.com/viewarticle/431514_side. Accessed September 27, 2007.
50. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007 Mar;36(3):152-8.
51. Alhamdani MS, Al-Kassir AH, Abbas FK, Jaleel NA, Al-Taee MF. Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin Pract. 2007;107(1):c26-34.
52. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov;17(11):833-7.
53. Bell JG, Sargent JR, Tocher DR, Dick JR. Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids. 2000 Jul;63(1-2):21-5.
54. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001 Jul;65(1):1-7.
55. Ward PE. Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders. Prostaglandins Leukot Essent Fatty Acids. 2000 Jul;63(1-2):65-8.
56. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004 Oct;71(4):201-4.
57. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001 Nov 1;120(1-2):170-9.
58. Grimm H, Mayer K, Mayser P, Eigenbrodt E. Regulatory potential of n-3 fatty acids in immunological and inflammatory processes. Br J Nutr. 2002 Jan;87 Suppl 1S59-S67.
59. De CR, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000 Jan;71(1 Suppl):213S-23S.
60. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007 Feb 15;61(4):551-3.
61. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11(2):131-42.
62. Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006 Aug;118(2):e534-6.
63. Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A. 2007 Jun;70(12):1046-51.
64. Soden SE, Lowry JA, Garrison CB, Wasserman GS. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila). 2007 Jun;45(5):476-81.
65. Ng DK, Chan CH, Soo MT, Lee RS. Low-level chronic mercury exposure in children and adolescents: meta-analysis. Pediatr Int. 2007 Feb;49(1):80-7.
66. Kirkman Laboratories. Detoxification of heavy metals in the treatment of autism. A Guide to Scientific Nutrition for Autism and Related Conditions. Lake Oswego, OR: Kirkman Laboratories; 2002.
67. Shannon M, Woolf A, Goldman R. Children's environmental health: one year in a pediatric environmental health specialty unit. Ambul Pediatr. 2003 Jan;3(1):53-6.
68. Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007 May 15;70(10):837-51.
69. Chisolm JJ, Jr. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations.J Toxicol Clin Toxicol. 2000;38(4):365-75.
70. Graziano JH, Lolacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr. 1992 Jan;120(1):133-9.
71. Karunasagar D, Krishna MV, Rao SV, Arunachalam J. Removal and preconcentration of inorganic and methyl mercury from aqueous media using a sorbent prepared from the plant Coriandrum sativum. J Hazard Mater. 2005 Feb 14;118(1-3):133-9.
72. Aga M, Iwaki K, Ueda Y, et al. Preventive effect of Coriandrum sativum (Chinese parsley) on localized lead deposition in ICR mice. J Ethnopharmacol. 2001 Oct;77(2-3):203-8.
73. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit. 2004 Mar;10(3):I33-9.
74. Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry. 2004 Sep;9(9):833-45.
75. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004 Sep;114(3):793-804.
76. Davidson PW, Myers GJ, Weiss B. Mercury exposure and child development outcomes. Pediatrics. 2004 Apr;113(4 Suppl):1023-9.
77. Halsey NA, Hyman SL. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics. 2001 May;107(5):E84.
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.
- Life Extension - Life Extension Vitamins
- Metagenics
- MetaKids
- Weight Management
- Glucose Management
- Longevity & Wellness
- Antioxidants
- Body Care
- Bones
- Brain
- Chinese / Mushrooms
- Digestion
- Energy / Sports
- Health Concerns
- Heart / Circulation
- Hormone / Prostate
- Immune
- Inflammatory Factors
- Intimacy
- Liver / Urinary
- Phyto Extracts
- Powdered Supplements
- Seasonal / Respiratory
- Vitamins / Multivitamins / Aminos / Minerals
- Life Extension CoQ10
- ~Metagenics X
- New Products
- RELATIONSHIP CONSULTANT AND COACH
